The International Myeloma Foundation Says Newly Published Study Confirms Survival Advantage With REVLIMID® And Further Advantages With Continuous Use In Newly Diagnosed Multiple Myeloma Patients Not Eligible For Transplant
9/4/2014 10:48:32 AM
NORTH HOLLYWOOD, Calif.--(BUSINESS WIRE)--The International Myeloma Foundation (IMF) says newly published data confirm REVLIMID® (lenalidomide) plus low-dose dexamethasone (Rd) improves survival and other measures of efficacy, compared to MPT (melphalan, prednisone, and thalidomide), a standard of care for newly diagnosed multiple myeloma patients who are not eligible for a stem cell transplant. The study also demonstrates that continuing use of REVLIMID-dexamethasone instead of stopping after a fixed number of treatments provides further advantages in multiple measures including overall survival, progression-free survival, time to disease progression, overall response rate, and duration of response. The data from the phase III FIRST® (MM-020/IFM 07 01) trial are in the September 4th issue of the prestigious New England Journal of Medicine and expand upon the preliminary presentation of the study that was highlighted at the ASH 2013 global medical conference.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by